The phenomenon of 'Ozempic babies' reveals deeper ethical issues in fertility care, exposing the reliance on body mass index (BMI) cutoffs that disproportionately affect marginalized communities.
These drugs, designed primarily for weight loss and diabetes management, have stirred unexpected conversations about infertility as individuals once deemed infertile report pregnancies after usage.
Fertility clinics often present BMI thresholds as safeguards, yet these cutoffs may unintentionally perpetuate a pattern of exclusion, obscuring the complex social factors that influence reproductive health.
The anecdotal nature of 'Ozempic babies' raises crucial questions about the ethical implications and efficacy of using medications designed for weight management in treating infertility.
Collection
[
|
...
]